Department of Nephrology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark Department of Nephrology, Herlev Hospital, University of Copenhagen, Herlev, Denmark.
Department of Cardiology, Gentofte Hospital, University of Copenhagen, Gentofte, Denmark.
Nephrol Dial Transplant. 2016 Oct;31(10):1654-62. doi: 10.1093/ndt/gfw073. Epub 2016 Apr 19.
Patients on dialysis treatment or living with a transplanted kidney have several risk factors for bone fracture, especially disturbances in mineral metabolism and immunosuppressive therapy. We describe the incidence of fracture in this retrospective national Danish cohort study and explore the influence of age, gender, comorbidity and prescribed medication.
By individual-level linkage between nationwide administrative registries, the risk of fracture was compared between the group of patients receiving chronic dialysis treatment and patients receiving their first renal transplant in the study period, using the Danish background population as reference group. All three groups were followed up until first fracture, emigration, death or end of study. Cox proportional hazard models with fracture as outcome were fitted to the data.
The hazard ratio (HR) for any fracture was 3.14 [95% confidence interval (95% CI):2.97-3.31] in the dialysis group and 1.94 (95% CI: 1.72-2.18) in the renal transplanted group. The HR remained increased, but was modified by adjustment for age, gender, comorbidity and prior fracture [dialysis group: 1.85 (95% CI: 1.75-1.95); renal transplanted group: 1.82 (95% CI: 1.62-2.06)]. Prescribed diuretics, lipid-modifying agents and proton pump inhibitors also modulated the fracture risk.
Patients on dialysis or living with a transplanted kidney have a significantly higher risk of fracture than the Danish background population. Differences in age, gender, drug use and comorbidity only partly explain this increased risk. Further studies are warranted to explore the reason for this increased fracture risk in patients on renal replacement therapy.
接受透析治疗或移植肾脏的患者存在多种骨折风险因素,尤其是矿物质代谢紊乱和免疫抑制治疗。我们在这项回顾性全国丹麦队列研究中描述了骨折的发生率,并探讨了年龄、性别、合并症和处方药物的影响。
通过全国性行政登记册的个体水平链接,在研究期间将接受慢性透析治疗的患者组与接受首次肾移植的患者组的骨折风险与丹麦背景人群进行比较。所有三组均随访至首次骨折、移民、死亡或研究结束。将骨折作为结局的 Cox 比例风险模型拟合至数据中。
透析组任何骨折的风险比(HR)为 3.14[95%置信区间(95%CI):2.97-3.31],移植肾组为 1.94(95%CI:1.72-2.18)。HR 仍然升高,但通过调整年龄、性别、合并症和既往骨折进行校正后有所改变[透析组:1.85(95%CI:1.75-1.95);移植肾组:1.82(95%CI:1.62-2.06)]。处方利尿剂、调脂药物和质子泵抑制剂也调节了骨折风险。
接受透析或移植肾脏的患者发生骨折的风险明显高于丹麦背景人群。年龄、性别、药物使用和合并症的差异仅部分解释了这种风险增加。需要进一步研究探索肾替代治疗患者骨折风险增加的原因。